文献速递结核与非结核分枝杆菌艾滋病与性传播感染

巴西结核病治疗中药物不良反应的预测模型

Prediction Models for Adverse Drug Reactions During Tuberculosis Treatment in Brazil.
PubMed 文献 · J Infect Dis · 2024-01-01

在巴西945例药物敏感肺结核患者中开发结核病治疗相关药物不良反应(TB-ADR)的预测模型。102例(11%)发生156次TB-ADR,主要预测模型含合并用药、HbA1c、饮酒、HIV血清阳性、BMI和年龄,c统计量为0.79(95%CI 0.74-0.83)。HIV血清阳性和合并用药增加TB-ADR风险。

要点

  • 945例中102例(11%)发生156次TB-ADR,82次(53%)为肝脏不良反应,121次(78%)为2级。
  • 主要预测模型含合并用药、HbA1c、饮酒、HIV血清阳性、BMI和年龄,c统计量0.79(95%CI 0.74-0.83)。
  • HIV血清阳性(HR 2.68,95%CI 1.75-4.09)和合并用药(HR 5.26,95%CI 2.63-10.52)增加TB-ADR风险。

核心结论

  • 含临床变量的模型和含NAT2的模型对TB-ADR均有高度预测能力。

研究设计与样本

  • 研究纳入945例开始标准结核治疗的药物敏感肺结核患者,通过bootstrapped backward selection开发预测模型,用Cox回归评估TB-ADR风险。

主要发现

  • 945例中102例(11%)发生156次TB-ADR。
  • TB-ADR中肝脏不良反应82次(53%),2级严重程度121次(78%),NAT2慢乙酰化者62次(61%)。
  • 主要预测模型含合并用药、HbA1c、饮酒、HIV血清阳性、BMI和年龄,c统计量0.79(95%CI 0.74-0.83),乐观校正斜率-0.09、截距0.94。
  • 以NAT2替代BMI的替代模型预测性能相似。
  • HIV血清阳性(HR 2.68,95%CI 1.75-4.09)和合并用药(HR 5.26,95%CI 2.63-10.52)增加TB-ADR风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tuberculosis (TB) treatment-related adverse drug reactions (TB-ADRs) can negatively affect adherence and treatment success rates. METHODS: We developed prediction models for TB-ADRs, considering participants with drug-susceptible pulmonary TB who initiated standard TB therapy. TB-ADRs were determined by the physician attending the participant, assessing causality to TB drugs, the affected organ system, and grade. Potential baseline predictors of TB-ADR included concomitant medication (CM) use, human immunodeficiency virus (HIV) status, glycated hemoglobin (HbA1c), age, body mass index (BMI), sex, substance use, and TB drug metabolism variables (NAT2 acetylator profiles). The models were developed through bootstrapped backward selection. Cox regression was used to evaluate TB-ADR risk. RESULTS: There were 156 TB-ADRs among 102 of the 945 (11%) participants included. Most TB-ADRs were hepatic (n = 82 [53%]), of moderate severity (grade 2; n = 121 [78%]), and occurred in NAT2 slow acetylators (n = 62 [61%]). The main prediction model included CM use, HbA1c, alcohol use, HIV seropositivity, BMI, and age, with robust performance (c-statistic = 0.79 [95% confidence interval {CI}, .74-.83) and fit (optimism-corrected slope and intercept of -0.09 and 0.94, respectively). An alternative model replacing BMI with NAT2 had similar performance. HIV seropositivity (hazard ratio [HR], 2.68 [95% CI, 1.75-4.09]) and CM use (HR, 5.26 [95% CI, 2.63-10.52]) increased TB-ADR risk. CONCLUSIONS: The models, with clinical variables and with NAT2, were highly predictive of TB-ADRs.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ridolfi F, Amorim G, Peetluk LS, et al. Prediction Models for Adverse Drug Reactions During Tuberculosis Treatment in Brazil. J Infect Dis. 2024. PMID: 38262629. doi:10.1093/infdis/jiae025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。